Oregon psilocybin program shows lasting mental health benefits

A real-world, multisite study led by Oregon Health & Science University found that state-regulated psilocybin services in Oregon provided relief from anxiety, depression, and PTSD, with about two-thirds of participants rating the experience as among the most meaningful of their lives. Published in JAMA Network Open, the study followed 346 adults across 24 licensed centers from late 2024 to 2026, reporting safety levels similar to controlled clinical settings. Senior co-author Adrianne Wilson-Poe described it as a landmark—the first large-scale, real-world monitoring of safety and mental health outcomes in Oregon’s program. Since Oregon legalized a nonmedical, supervised model in 2023, the program has reached tens of thousands of adults, indicating substantial scale beyond clinical trials. Three-month data showed significant reductions in moderate-to-severe depression, anxiety, and PTSD symptoms among participants. However, industry observers warn that looming fee increases could threaten the program’s viability, even as the safety and effectiveness data bolster support for the model.